NEOPLASM METASTASIS

This expanded access program provides vepugratinib, an oral drug, to people with metastatic urothelial carcinoma or other solid tumors that have a specific FGFR3 genetic change. Participants must have exhausted other approved treatments, including erdafitinib for bladder cancer, …

This study tests whether adding a new drug (LY4064809) to standard hormone therapy and CDK4/6 inhibitors can better control advanced HR+ HER2- breast cancer with a PIK3CA mutation. About 920 adults who have not had prior treatment for advanced disease will participate. The goal i…

This study tests whether adding a new targeted medicine (vepugratinib) to two standard cancer drugs can help people with advanced bladder cancer that has a specific genetic change (FGFR3). About 450 adults whose cancer has spread or cannot be removed by surgery will take part. Th…

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This early-stage trial tests a new drug called LY4175408, which is designed to seek out and attack cancer cells that have a specific marker (PTK7). The study includes 240 people with advanced lung, endometrial, or triple-negative breast cancers that have not responded to standard…

This global study is testing whether adding the experimental drug olomorasib to standard immunotherapy and chemotherapy can help people with a specific genetic subtype of advanced non-small cell lung cancer (KRAS G12C mutation). About 1,264 participants will receive either the ne…

This early-stage trial is testing a new oral drug called LOXO-435, alone or with other cancer medicines, in people with advanced solid tumors that have a specific change in the FGFR3 gene. The study aims to find the right dose and check for safety and early signs of effectiveness…

This large Phase 3 study tests a new medicine called Sofetabart Mipitecan for people with ovarian, fallopian tube, or peritoneal cancer. It includes two groups: those whose cancer stopped responding to platinum chemotherapy within six months (platinum-resistant), and those whose …

This study tests two different chemotherapy combinations for people with metastatic colorectal cancer that has spread and needs a second treatment. About 280 adults will be randomly assigned to receive either FOLFIRI or irinotecan, with or without bevacizumab. The goal is to see …

This study combines two treatments—laser heat to destroy tumors near the spinal cord and precise radiation—to better control spine tumors that have spread from other cancers. About 60 adults with solid tumors will receive both therapies. The goal is to improve tumor control, redu…

This study is for people with endometrial cancer that has come back or spread to a few other spots. It tests a new drug called cadonilimab given together with standard chemotherapy and radiation. The goal is to see if this combination can shrink tumors and help people live longer…

This early-stage trial is testing a new three-drug combination for people with head and neck cancer that has come back or spread. The drugs include a targeted therapy (zanzalintinib), an immunotherapy (pembrolizumab), and another targeted antibody (cetuximab). The main goal is to…

This study is observing about 800 adults with advanced breast cancer (HER2-positive, low, or ultralow) who are receiving the drug trastuzumab deruxtecan as part of their normal care in Germany. Researchers are tracking how long patients stay on the drug before switching treatment…

This study is tracking 3000 men with prostate cancer from Guadeloupe and Brittany to understand why the disease progresses differently in different people. Researchers will collect blood, urine, and saliva samples along with health data to look for genetic, environmental, and lif…